Amylyx Pharmaceuticals, Inc. AMLX 深 滬
已收盤 09-19 16:00:00 美东时间
13.31
+0.060
+0.45%
華盛通- 最 高13.50
- 今 開13.28
- 成交量 359.84万股
- 最 低 12.91
- 昨 收 13.25
- 總市值 14.24亿
- 52周最高 13.50
- 市盈率 靜 --
- 換手率 3.36%
- 52周最低 2.60
- 委 比 91.01%
- 總股本 1.07亿
- 歷史最高 41.9297
- 量 比 1.92
- 振 幅 4.45%
- 歷史最低 1.575
- 每 手 1
- 風險率 2.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
Amylyx股价上涨10.9%，此前完成1.75亿美元融资
美股周三早盘，制药商Amylyx Pharmaceuticals（AMLX）股价上涨10.9%，此前该公司宣布以每股10美元的价格完成1.75亿美元的公开发...
09-10 22:51
Amylyx Pharmaceuticals prices $175M public offering
Amylyx Pharmaceuticals (NASDAQ:AMLX) priced an underwritten public offering of 17.5M shares at a public offering price of $10.00 per share. All of the shares of common stock are being offered by Amy...
09-10 13:38
Amylyx Pharmaceuticals Announces An Underwritten Public Offering Of Its Common Stock; Financial Terms Not Disclosed
Amylyx Pharmaceuticals (NASDAQ:AMLX) Has Initiated An Underwritten Public Offering Of Its Common Stock, With All Shares Being Offered By The Company. The Underwriters Have A 30-day Option To Purchase Up To 15% Additional
09-10 04:03
Amylyx Pharma To Discontinue ORION Program Of AMX0035 In Adults Living With Progressive Supranuclear Palsy
- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24- AMX0035 continued to be generally well-toleratedAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company")
08-27 19:15
Which under-the-radar winners have the best chance for further gains?
Looking for smaller stocks that have attracted strong investor interest so far in 2025, but are still positioned for further gains? The list below is meant to focus on those names. It contains stocks ...
08-07 22:15
Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Amylyx reports strong Phase 2b trial data for avexitide, showing 64% fewer hypoglycemic events in patients with post-bariatric hypoglycemia.
07-15 02:15
